{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:23:00Z","timestamp":1787865780261,"version":"build-2784847793"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002554","name":"AIDS Healthcare Foundation","doi-asserted-by":"publisher","award":["20181796"],"award-info":[{"award-number":["20181796"]}],"id":[{"id":"10.13039\/100002554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Safe and efficacious alternative treatment options for syphilis are necessary. This randomized, 2-arm, noncomparative pilot study evaluated the efficacy of oral cefixime 400 mg in achieving a \u22654-fold rapid plasma reagin titer decrease by 3 or 6 months after treatment. The proportion of cefixime arm participants treated successfully was 87% (95% confidence interval, 69%\u2013100%; 13\/15).<\/jats:p>\n                  <jats:p>Clinical Trials Registration. NCT03752112.<\/jats:p>","DOI":"10.1093\/cid\/ciab187","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T12:45:19Z","timestamp":1614257119000},"page":"907-910","source":"Crossref","is-referenced-by-count":33,"title":["Clinical Efficacy of Cefixime for the Treatment of Early Syphilis"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1486-1130","authenticated-orcid":false,"given":"Chrysovalantis","family":"Stafylis","sequence":"first","affiliation":[{"name":"Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kori","family":"Keith","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tellalian","sequence":"additional","affiliation":[{"name":"Department of Medicine, AIDS Healthcare Foundation, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Burian","sequence":"additional","affiliation":[{"name":"Department of Medicine, AIDS Healthcare Foundation, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Millner","sequence":"additional","affiliation":[{"name":"Department of Medicine, AIDS Healthcare Foundation, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D","family":"Klausner","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"2021090721191039000_CIT0001","volume-title":"WHO guidelines for the treatment of Treponema pallidum (syphilis)","author":"World Health Organization","year":"2016"},{"key":"2021090721191039000_CIT0002","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archinternmed.2012.2706","article-title":"Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort","volume":"172","author":"Jarzebowski","year":"2012","journal-title":"Arch Intern Med"},{"key":"2021090721191039000_CIT0003","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1097\/00002030-200410210-00012","article-title":"Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections","volume":"18","author":"Buchacz","year":"2004","journal-title":"AIDS"},{"key":"2021090721191039000_CIT0004"},{"key":"2021090721191039000_CIT0005","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1001\/jama.2014.13259","article-title":"Treatment of syphilis: a systematic review","volume":"312","author":"Clement","year":"2014","journal-title":"JAMA"},{"key":"2021090721191039000_CIT0006","author":"New York City Department of Health and Mental Hygiene Bureau of Sexually Transmitted Infections; New York City STD Prevention Training Center","year":"2019"},{"key":"2021090721191039000_CIT0007","first-page":"37","article-title":"Biology of Treponema pallidum: correlation of functional activities with genome sequence data","volume":"3","author":"Norris","year":"2001","journal-title":"J Mol Microbiol Biotechnol"},{"key":"2021090721191039000_CIT0008","volume-title":"Cefixime highlights of prescribing information","author":"US","year":"2017"},{"key":"2021090721191039000_CIT0009","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1186\/s13063-020-04885-z","article-title":"Clinical trial protocol to evaluate the efficacy of cefixime in the treatment of early syphilis","volume":"21","author":"Mehta","year":"2020","journal-title":"Trials"},{"key":"2021090721191039000_CIT0010","article-title":"Lupin Pharmaceuticals. Suprax 400 mg, package insert. 2007."},{"key":"2021090721191039000_CIT0011","first-page":"71","article-title":"The great imitator revealed: syphilis","volume":"27","author":"Klausner","year":"2019","journal-title":"Top Antivir Med"},{"key":"2021090721191039000_CIT0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12879-020-04980-1","article-title":"Phase II trial evaluating the clinical efficacy of cefixime for treatment of active syphilis in non-pregnant women in Brazil (CeBra)","volume":"20","author":"Taylor","year":"2020","journal-title":"BMC Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab187\/37253886\/ciab187.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/5\/907\/40326563\/ciab187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/5\/907\/40326563\/ciab187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T17:19:29Z","timestamp":1631035169000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/5\/907\/6152217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,2,26]]},"published-print":{"date-parts":[[2021,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab187","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,2,26]]}}}